Antibody and inhibitor and transformation method and transformation kit using the same

a technology of inhibitors and transformation methods, applied in the direction of immunoglobulins, peptides, antibody medical ingredients, etc., can solve the problems of not being able to achieve the improvement of infection efficiency and not yet been clarified, so as to improve the infection efficiency of virus vectors, suppress immune responses, and enhance the effect of infection efficiency

Inactive Publication Date: 2005-07-14
JAPAN SCI & TECH CORP
View PDF1 Cites 33 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012] The object of the present invention is to provide (i) an antibody against a Toll-like receptor having a function for inhibiting production of type I interferon which is induced by a viral double-stranded RNA, (ii) an inhibitor capable of suppressing immune response against ...

Problems solved by technology

However, the improvement of the infection efficiency has not yet been achieved, and is the largest factor which prevents application of the virus vector as a multipurpose vector.
Recently, it is a problem to resolve the mechanism of the immune system how an innate im...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody and inhibitor and transformation method and transformation kit using the same
  • Antibody and inhibitor and transformation method and transformation kit using the same
  • Antibody and inhibitor and transformation method and transformation kit using the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0065] In order to identify ligands for TLR3 by checking expression of TLR3 protein level and localization of TLR3 in terms of protein, the monoclonal antibody against human TLR3 was generated as the inhibitor according to the present invention.

[0066] That is, first, BALB / c mice were immunized with Ba / F3 cells stably expressing Flag-tagged (fluorescence-tagged) human TLR3, and then, spleen cells of the mice were fused with NS-1 myeloma cells so as to obtain an antibody producing hybridoma. From the antibody producing hybridoma, a monoclonal antibody against TLR3 was chosen by cell-surface staining of the same TLR3 transfectants used for immunization, so as to establish a monoclonal antibody against TLR3. The monoclonal antibody was named as TLR3.7. In the monoclonal antibody TLR3.7, immunoglobulin subclass was IgG1 and an L-chain was type κ.

[0067] Further, as a control, a monoclonal antibody against TLR2 was generated in the same manner as in the monoclonal antibody TLR3.7. The mo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to view more

Abstract

The present invention provides a monoclonal antibody which specifically binds to human Toll-like receptor 3. Further, the present invention provides an inhibitor which (a) suppresses a double-stranded RNA-mediated immune response in a cell which expresses Toll-like receptor recognizing the double-stranded RNA and produces type I interferon, and (b) includes an antibody, which binds to the Toll-like receptor and inhibits production of the type I interferon. Particularly, the antibody is a monoclonal antibody against human Toll-like receptor 3. Further, the present invention provides a transfection method comprising the step of infecting a cell which expresses Toll-like receptor recognizing a double-stranded RNA and produces type I interferon by expressing Toll-like receptor recognizing a double-stranded RNA with a recombined virus vector, in which a gene of interest has been inserted, under the inhibitory condition for production of the type I interferon by using an inhibitor including an antibody which binds to the Toll-like receptor. Thus, it is possible to provide (i) an inhibitor which inhibits the production of the type I interferon induced by a virus double-stranded RNA so as to suppress an immune response against the virus, and (ii) a transfection method or a transfection kit whereby a transfection efficiency is improved without enhancing an infectious capacity of a virus vector.

Description

TECHNICAL FIELD [0001] The present invention relates to (i) an antibody specifically bound to human Toll-like receptor 3, (ii) an inhibitor for blocking a signaling induced by double-stranded RNA (ribonucleic acid) so as to suppress a double-stranded RNA-mediated immune response in a cell which produces type I interferon (interferon-α and interferon-β) by expressing the Toll-like receptor recognizing the double-stranded RNA on the surface, (iii) a transfection method or a transfection kit using the antibody and the inhibitor so as to carry out transfection with a recombined RNA virus vector in which a gene of interest is inserted. BACKGROUND ART [0002] It is said that there have been viruses since so early stage of birth of life and have been evolving while contributing to evolution of organisms. There are many viruses having RNA as a gene (RNA viruses), and 90% of plant viruses are RNA viruses. [0003] Recently, a method for introducing genetically-engineered genes into mammalian ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/09A61K39/395A61P31/12C07K16/28
CPCA61K2039/505C07K16/2896C07K16/28A61P31/12
Inventor MATSUMOTO, MISAKOSEYA, TSUKASA
Owner JAPAN SCI & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap